NBE Therapeutics AG
http://www.nbe-therapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NBE Therapeutics AG
Ipsen Dives Back Into Dealmaking With First ADC Pact
The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.
Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds
Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice